Physician profile
David S Bub
NPI 1558330621
$1,486.74
in general payments reported to CMS, 2019-2025
19 companies · $13.81 in 2025
The $13.81 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $59.80 · 2021: $286 · 2022: $223 · 2023: $348 · 2024: $299 · 2025: $13.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $290.35 | 2020-2025 | Gattex |
| Medtronic, INC. | $225.70 | 2021-2022 | |
| Thd America, INC. | $207.48 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $178.50 | 2019-2023 | Clenpiq, Rebyota |
| Axonics, INC. | $172.69 | 2022-2024 | Axonics |
| Braintree Laboratories, INC. | $66.46 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.59 | 2019 | |
| Shire North American Group INC | $49.25 | 2019 | |
| Pfizer INC. | $43.30 | 2019-2021 | |
| Medtronic USA, INC. | $33.01 | 2019 | |
| Celgene Corporation | $31.23 | 2023 | Zeposia |
| Alexion Pharmaceuticals, INC. | $24.98 | 2023 | Ultomiris |
| Teleflex LLC | $18.01 | 2024 | Solesta |
| Merck Sharp & Dohme LLC | $17.86 | 2020 | |
| Mission Pharmacal Company | $17.10 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $16.23 | 2022 | |
| Integra Lifesciences Corporation | $14.91 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $14.28 | 2024 | Exparel |
| Janssen Biotech, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.